RCKT241115P25000
- 0.00
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT) and Rocket Pharmaceuticals (RCKT)
TD Cowen Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
Positive Outlook for Rocket Pharmaceuticals Amidst Significant Trial Progress and Regulatory Engagement
Express News | Rocket Pharmaceuticals Inc : JP Morgan Cuts Target Price to $49 From $54
Rocket Pharmaceuticals Positioned for Growth With Promising Pipeline and Strategic Advancements
William Blair Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $55
Strong Buy Recommendation for Rocket Pharmaceuticals Driven by Strategic Positioning and Promising Pipeline Developments
Rocket Pharmaceuticals Q3 2024 GAAP EPS $(0.71) Beats $(0.75) Estimate
10-Q: Quarterly report
Rocket Pharmaceuticals 3Q Loss/Shr 71c >RCKT
Press Release: Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
KBRA Assigns Preliminary Ratings to RCKT Mortgage Trust 2024-CES8 (RCKT 2024-CES8)
Scotiabank Initiates Rocket Pharmaceuticals at Sector Outperform With $50 Price Target
We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rocket Pharmaceuticals Price Target Maintained With a $38.00/Share by Canaccord Genuity
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $38
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $38 to $53
On Sep 18, major Wall Street analysts update their ratings for $Rocket Pharmaceuticals(RCKT.US)$, with price targets ranging from $38 to $53.Morgan Stanley analyst Michael Ulz maintains with a buy